FDA Clearance Tracker · P230035-S006
AGENT Paclitaxel-Coated Balloon Catheter
Last checked: Nov 20, 2026Latest source record: Feb 11, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Feb 11, 2026
Approved
Time to decision
265 days
Received May 22, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P230035-S006
- Device name
- AGENT Paclitaxel-Coated Balloon Catheter
- Applicant
- Boston Scientific Corporation
- Applicant location
- Maple Grove, MN
- Received
- May 22, 2025
- Decided
- Feb 11, 2026
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
- Original approval
- P230035
Device type
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
a manufacturing site change to include Boston Scientific Ltd., located at Ballybrit Business Park, Galway, Ireland, for drug coating manufacturing, packaging and labeling for the Agent Monorail Paclitaxel Coated Balloon Catheter
Source documents
Other decisions for Boston Scientific Corporation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- SpaceOAR Flex System510(k)
K262151 · Decided Sep 11, 2026 · 78 days after receipt
Device type: Hydrogel Spacer (OVB) · Radiology & Imaging
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.